Effigel

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Effigel

Property Description
Active Ingredient Diclofenac (as Diclofenac Epolamine)
Form Topical Gel
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common Use (General) Relief of localized pain and inflammation
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Effigel?

Effigel is a synthetic medicinal product that contains the active substance Diclofenac, which is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). This classification means the substance is derived from phenylacetic acid and its primary function is to modulate the body’s inflammatory response. The product is recognized as a single-ingredient product, with its therapeutic profile stemming from the established activity of the Diclofenac compound. This anti-inflammatory mechanism supports its suitability for addressing localized painful conditions. The medicine is designed to act against the biological processes that cause swelling and discomfort.

Composition and Pharmaceutical Form

The medicine is formulated as a topical gel, a semi-solid preparation intended strictly for cutaneous administration (application to the skin surface). The active substance is utilized as the Diclofenac epolamine salt, which is integrated into a specialized hydrogel or hydroalcoholic base. This particular salt formulation is a distinctive feature of the product, engineered for optimized percutaneous absorption.

The choice of a topical gel distinguishes it from oral NSAID forms, as it is engineered to maximize local delivery to the affected soft tissues, such as in the case of localized tendon soreness. Pharmacokinetic data for topical systems indicate that the therapeutic effect occurs with minimal systemic exposure compared to oral intake. This supports the principle that the therapeutic action is concentrated where the product is applied.

General Purpose and Action Principle

The general purpose of Effigel is to provide localized relief from symptoms of pain and inflammation through its designated pharmacological action. This effect is achieved because Diclofenac functions as a cyclooxygenase inhibitor, actively interrupting the biological pathway responsible for the synthesis of prostaglandins, which are key chemical mediators of inflammation. By inhibiting this process, the medicine provides both a direct anti-inflammatory effect and an analgesic (pain-relieving) benefit at the site of application.

Regulatory References

  1. Diclofenac - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Effigel?

Official Adverse Reactions and Safety Profile

The safety profile for this diclofenac topical gel is predominantly characterized by effects occurring at the site of application. Regulatory documents classify these reactions by frequency, focusing on adverse events observed across different physiological systems.

Frequency Classification of Side Effects

Adverse reactions that are frequently observed are primarily localized to the skin and subcutaneous tissue:

  • Very Common (affecting ge 1 in 10): Application site pruritus (itching) and dermatitis.
  • Common (affecting ge 1 in 100 to < 1 in 10): Application site erythema (redness) and rash. Systemic reactions documented at this frequency include headache and nausea.
  • Uncommon to Very Rare: Less frequent adverse effects include dizziness, paresthesia, photosensitivity reactions, and serious reactions such as bullous dermatitis and urticaria.

Serious Adverse Reactions and Safety Constraints

As the active substance, diclofenac, belongs to the Nonsteroidal Anti-inflammatory Drug (NSAID) class, the official labeling includes mandatory warnings for rare but serious systemic risks, which govern the overall safety framework:

  • NSAID Class Risks: The regulatory text addresses the potential for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (including bleeding and ulceration), which can occur with NSAID exposure. The risk for these serious events may increase with the duration of use.
  • Use Restrictions: The product is officially contraindicated for use on non-intact skin, such as wounds or open injuries. Use is also restricted during the third trimester of pregnancy (starting at 30 weeks gestation) due to risks to the fetus. Caution is advised for older adults and individuals with pre-existing hepatic, renal, or cardiac impairment.

Overdose and Emergency Response

The official regulatory profile for Effigel notes that overdose is unlikely to occur from appropriate topical application due to the low rate of systemic absorption of the diclofenac component. The primary risk of serious adverse events arises from accidental oral ingestion of the gel, which can lead to significant systemic exposure to the active substance, a Nonsteroidal Anti-inflammatory Drug (NSAID).

In the event of oral ingestion, potential manifestations are anticipated to be consistent with acute NSAID overdose, including gastrointestinal effects such as nausea, vomiting, and abdominal pain, along with central nervous system effects like headache, dizziness, drowsiness, and convulsions. Severe or life-threatening outcomes can include fatal cardiovascular thrombotic events (myocardial infarction or stroke), fatal gastrointestinal bleeding or perforation, and severe allergic reactions.

Regulatory agencies mandate that if the product is swallowed, you must get medical help right away or contact a Poison Control Center. Seek emergency help immediately if any signs of a serious reaction, such as anaphylaxis, occur. Overdose management is symptomatic and supportive; no specific antidote is known. Procedures for managing ingestion may include emptying the stomach by vomiting or lavage. Elderly patients or those with existing heart, liver, or kidney dysfunction are noted to be at increased risk for severe adverse outcomes following systemic exposure.

Therapeutic Uses of Effigel

What Effigel Treats: Main Uses and Benefits

Effigel is a product that can help temporarily relieve aches and pains in muscles and joints. It is used to help manage discomfort associated with common conditions and minor trauma, supporting localized pain management. The indications for the product include simple backache, lumbago, strains and sprains (involving muscles, tendons, and/or ligaments), and arthritis.

A key benefit is the focused, local relief of symptoms, which may help enhance comfort during recovery from a minor injury. The product is commonly used following acute, localized injuries. The local application is intended to help enhance patient comfort during the recovery process.


Quick Fact: Relief for Muscle & Joint Pain

Eligibility and Restrictions for Use

The official eligibility for Effigel is defined by government regulatory bodies based on specific patient characteristics and pre-existing conditions.


Populations Strictly Contraindicated

Use is absolutely prohibited for individuals with a known hypersensitivity to Diclofenac or any history of asthma, hives, or acute rhinitis precipitated by aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). The medicine is also contraindicated during the entire third trimester of pregnancy and must not be applied to damaged or non-intact skin, such as open wounds or eczema.


Age-Related Eligibility

The medicine is approved for use in adults (18 years and older). Use in children under 14 years is not recommended because efficacy and safety have not been established. Regulatory documents advise caution when the medicine is used by the elderly population who may require closer monitoring.


Restrictions and Special Considerations

Use is not recommended during the first and second trimesters of pregnancy or while breastfeeding. Special regulatory caution is mandated for patients with underlying severe renal or hepatic impairment, or a history of gastrointestinal ulcers, due to the NSAID class of the active ingredient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The systemic absorption of diclofenac from Effigel is generally low; however, the potential for interactions, primarily extrapolated from systemic non-steroidal anti-inflammatory drugs (NSAIDs), should be considered, as documented in regulatory information.

Documented Interaction Categories

Category Interacting Substances / Constraints
Pharmacodynamic Risk Amplification Co-administration with oral NSAIDs (including aspirin), anticoagulants, antiplatelet agents, SSRIs, or SNRIs may increase the risk of serious adverse effects, notably gastrointestinal bleeding and renal impairment.
Efficacy Reduction Diclofenac may reduce the antihypertensive and diuretic effects of ACE inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics.
Systemic Drug Level Modification Diclofenac may increase the serum concentrations of digoxin, lithium, and methotrexate. Strong CYP2C9 inhibitors (e.g., voriconazole) may increase systemic diclofenac levels.

Official Restrictions and Notes

Official labeling generally restricts the use of Effigel immediately before or after Coronary Artery Bypass Graft (CABG) surgery. Specific warnings note that elderly patients are at greater risk for serious outcomes when co-administering interacting medicines. The product information instructs to allow the treated area to be completely dry before applying other topical products.

Mechanism of Action

Inhibition of Prostaglandin Synthesis

This mechanism involves the drug's active ingredient functioning as a non-selective enzyme inhibitor of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking the active sites of these enzymes, the drug interferes with the Arachidonic Acid Cascade . This action prevents the conversion of a precursor molecule into prostaglandins, which are lipid-based chemical mediators involved in local physiological responses.


Adjustment of Local Prostaglandin Synthesis Dynamics

The active ingredient is formulated for peripheral action, meaning its effect is concentrated within the tissues at the application site. This targeted local concentration leads to a reduction in the overall level of eicosanoids within the affected area. The limitation in mediator synthesis alters the dynamics of local tissue signaling. This results in the physiological consequence of lower rates of exudate formation and a modification of localized nociceptive signaling patterns.

Dosage and Administration Information

How to Use Effigel: Official Administration Guidelines

Effigel (Diclofenac Epolamine topical gel) is strictly administered via the cutaneous route, meaning it is applied only to the surface of the skin at the affected site. This formulation is intended solely for external use and must not be ingested or applied to eyes, mucous membranes, or open wounds.

Standard Dosing and Frequency

The application schedule typically involves use up to four times daily (QID). The quantity of gel used for each application is measured and should generally not exceed 2 grams for smaller upper extremities or 4 grams for larger lower extremities, as defined for certain indications like osteoarthritis pain. The total daily dosage applied to all affected areas should not surpass 32 grams. A minimum interval between applications is generally required to maintain a consistent dosing pattern.

Application Technique and Constraints

The gel should be applied thinly and gently rubbed into the skin until it is absorbed. After application, hands must be washed thoroughly unless the hands are the area being treated. The product is restricted to use on intact, non-diseased skin and must not be used with an airtight occlusive dressing or external heat.

Duration and Specific Populations

Effigel is generally intended for short-term use. For acute pain or injury, the standard course of treatment is limited and typically reviewed after 7 days, based on the principle of using the lowest effective dosage for the shortest duration necessary. While adolescents aged 14 and over may use the product according to adult dosing guidelines, use is typically restricted for children under 14 years due to insufficient data.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Effigel


Evidence for Acute Pain from Minor Injuries

The primary evidence base for topical diclofenac in acute conditions comes from Randomized Controlled Trials (RCTs), comparing the topical application against an inactive vehicle (placebo) or other treatments included in the study design. These short-term trials were used in research exploring how symptoms change over time. They mainly involved Adults with recent, localized injuries like strains, sprains, or contusions, which are conditions associated with acute or disruptive episodes.

In these trials, research examined patient-reported outcomes describing perceived discomfort, specifically measuring changes in pain intensity, as well as outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies where the active gel application was studied alongside the inactive control, reporting measurements of changes over the short study period.


Evidence for Chronic Pain in Osteoarthritis (OA)

For chronic conditions like Osteoarthritis (OA) of joints accessible by topical application, the evidence includes Randomized Controlled Trials (RCTs). These studies explored symptom changes in populations, generally Adults, with OA. Research examined outcomes related to physical discomfort and functional limitations, primarily using standardized tools to measure changes in chronic pain, joint stiffness, and physical ability.

Studies monitored responses over defined time intervals, with efficacy trials commonly lasting 4 to 12 weeks. Data show patterns related to measured changes in pain and function observed in studies comparing the active gel to the vehicle control. This research provides insight into short-term changes in these conditions marked by functional limitations.


Research Gaps and Areas of Uncertainty

The research landscape highlights that follow-up durations were limited in many controlled trials, particularly for defining sustained patterns of effect in chronic OA. Long-term outcomes are not well characterized by controlled trials extending for a year or more. Research design and methodology vary across studies when comparing specific formulation features. Findings describe group patterns, not personal outcomes, which reflects the inherent uncertainty in applying clinical trial results to every individual situation.

Key Studies & References Topical diclofenac for pain relief: advances in formulation and technology (Review)

Frequently Asked Questions (FAQ)

Common questions about Effigel (FAQ)


Q: Why are there warnings about alcohol use with some treatments similar to Effigel?

A: Official regulatory warnings for the NSAID class of medicines, which includes the active ingredient in Effigel, highlight a potential risk with alcohol use. Consuming alcohol, particularly heavy consumption, may be associated with an increased risk of serious gastrointestinal problems, such as bleeding, linked to the NSAID class.

Q: Is Effigel an antibiotic or an antiseptic?

A: According to official product information, Effigel is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not an antibiotic, which fights bacteria, nor is it an antiseptic, which prevents the growth of microorganisms on skin.

Q: Does Effigel need a prescription, or is it over-the-counter?

A: The most common concentration of this type of medicine, diclofenac 1% gel, has generally been approved by regulatory bodies to be sold over-the-counter (OTC) in certain regions. This means it is available without a prescription in those markets.

Q: Can Effigel cause a burning or stinging sensation?

A: Official information lists common skin reactions at the application site, such as itching (pruritus) and redness (erythema). The most common skin reactions are itching and redness. Less commonly, a temporary burning or stinging sensation has also been reported.

Q: What is the purpose of the applicator that comes with Effigel?

A: If a dosing card or applicator is included, its main function is to help measure the amount of gel to apply to the affected area, supporting adherence to the prescribed dosage limit. This helps ensure that the volume used for each application is consistent with the regulatory guidelines.

Q: Is there a generic version of Effigel available?

A: Yes. Regulatory bodies, such as the FDA, have approved Abbreviated New Drug Applications (ANDAs) for generic versions of diclofenac sodium topical gel, 1%. These generic versions contain the same active ingredient as the brand-name product.

Q: Can Effigel be used by women who are post-menopausal?

A: The medicine is approved for use in adults (18 years and older). Regulatory information advises caution for use in the elderly population, which may necessitate professional monitoring. There are no specific restrictions for post-menopausal status alone.

Q: Are there any foods or drinks that should be avoided while using Effigel?

A: Official product information does not list any specific food restrictions when using the topical gel. However, due to the low systemic absorption, the general NSAID class warning against heavy alcohol consumption still applies to avoid increasing the risk of gastrointestinal issues.

Q: Can men use Effigel for any reason?

A: Yes, this medicine is officially indicated for the relief of localized pain and inflammation, such as pain from osteoarthritis, in adults. These regulatory indications are not limited by gender.

Q: Are there any known long-term effects of using Effigel regularly?

A: The product is generally intended for short-term use. Long-term use or application over large areas could potentially increase the likelihood of systemic NSAID side effects, such as cardiovascular or gastrointestinal risks, as noted in the safety warnings.

Q: What kind of research supports the use of Effigel?

A: The regulatory approval for this medicine is supported by clinical studies, primarily Randomized Controlled Trials (RCTs). These trials compared the active gel against an inactive vehicle (placebo) to evaluate its effectiveness for conditions like localized pain and inflammation.

Q: Why is Effigel sometimes recommended by doctors?

A: Healthcare providers may recommend the gel for localized pain relief because its active ingredient (diclofenac) is an NSAID. This mechanism works by inhibiting the production of chemical mediators that cause pain and swelling directly at the site of application in the body's tissues.

Q: What are the inactive ingredients in Effigel?

A: Official labeling lists the inactive ingredients, which typically include a hydrogel or hydroalcoholic base. These components are specifically formulated to ensure the active substance is absorbed effectively through the skin for targeted relief.

Q: Is it okay to use Effigel just before or after swimming?

A: The product label advises waiting at least one hour before showering or bathing to allow the gel to absorb into the application site. This ensures the medicine is not washed away immediately after use.

Q: Has Effigel been studied in different age groups of women?

A: Clinical use guidelines cover adolescents (aged 14 and over), adults, and the elderly. However, use in children under 14 is generally restricted due to limited data to establish safety and effectiveness for this age group.

Q: Are the side effects of Effigel common or rare?

A: Side effects are officially classified by frequency. Local skin reactions like itching and dermatitis are considered Very Common (affecting a significant number of people). Conversely, the risk of serious systemic NSAID effects is considered rare.

Q: Can Effigel be used to prevent an infection?

A: No. Effigel is an NSAID intended to relieve pain and inflammation. It does not have regulatory approval for preventing or treating infections, as it is not an antimicrobial medicine.

Q: Does the application time of day matter for Effigel?

A: Regulatory guidelines specify the maximum number of times the gel can be applied daily and require a minimum interval between applications. As long as this schedule is maintained, official clinical trials do not specify a required time of day for application.

Q: What should I look out for as a sign of an allergic reaction to Effigel?

A: Signs of a serious allergic reaction may include breathing difficulties, wheezing, hives, or an itchy rash. If any symptoms suggesting a serious allergic reaction appear, it is important to contact a healthcare professional or seek emergency care right away.

Q: Can Effigel be used after a gynecological procedure?

A: Regulatory warnings restrict its application on non-intact skin or open wounds. It should not be used on surgical sites unless a healthcare provider explicitly confirms it is appropriate for the specific situation.

Q: Does Effigel require any special cleanup or disposal?

A: Unused or expired gel should be disposed of by following local government regulations or by using a medication take-back program. When not in use, the medicine should be kept in its closed container.

Q: Is Effigel approved in countries outside of the US?

A: Similar topical diclofenac products are approved and regulated by numerous international health authorities. The regulatory text cites guidance from health bodies in the US, Europe (EMA), and the UK (MHRA).

Q: What is Effigel typically used for in women's health?

A: The product is officially indicated for the relief of localized pain and inflammation, such as pain from osteoarthritis, in adults. Official regulatory texts do not mention specific gynaecological uses for this cutaneous gel.

Q: Does Effigel help with dryness or just discomfort?

A: The active ingredient in Effigel is an NSAID, which provides pain-relieving (analgesic) and anti-inflammatory effects to reduce discomfort. It is not formulated or officially indicated as a moisturizing or lubricating product for dryness.

Q: Can Effigel interact with common pain relievers?

A: Yes, official warnings cite a potential for interaction if the topical gel is used at the same time as oral NSAIDs, including aspirin. This combination can increase the risk of serious adverse effects.

Q: Is Effigel safe to use if I am trying to conceive?

A: NSAIDs may affect fertility, and regulatory information notes restrictions during pregnancy (contraindicated in the third trimester). It is recommended that individuals planning to become pregnant discuss medication use with a healthcare provider.

Q: What is the evidence regarding Effigel's safety during breastfeeding?

A: Regulatory documents state that use during breastfeeding is generally not recommended. This is because the active substance may be able to pass into breast milk, which could potentially lead to effects for the child.

Q: What are the typical ingredients found in the 'other medicines and products' Effigel might interact with?

A: Official warnings cite interactions for specific drug classes, including oral NSAIDs (like ibuprofen), blood thinners (anticoagulants), certain types of antidepressants (SSRIs), and some blood pressure medications (such as ACE inhibitors).

How should Effigel be stored and disposed of?

How to Store and Dispose of Diclofenac Topical Gel

The storage of diclofenac topical gel must adhere to specific regulatory standards to maintain product quality. The gel must be stored at controlled room temperature, specifically between 20^circC to 25^circC (68^circF to 77^circF). It is mandatory to keep the product from freezing and to store it away from excessive heat, moisture, and direct light. The gel should be kept in its closed container.

Child Safety and Disposal

The medicine must be stored out of the sight and reach of children and pets. For disposal, unused or expired diclofenac topical gel should be discarded by following local regulations or utilizing a medication take-back program where available, as directed by official pharmaceutical waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Effigel found in:

A-Z Index: